Candidemia is a serious complication in patients following allogeneic blood, marrow, and organ transplantation. Fourteen patients developed nosocomial fungemia among 204 allogeneic marrow transplants performed during 1997-1999. Incidence of hematogenous candidiasis was 6.8 per 100 allogeneic BMT. All 14 had an indwelling central venous catheter (CVC) and fluconazole (100-200 mg daily) was given prophylactically. In 11 (78.5%) neutropenic patients, duration between agranulocytosis and diagnosis of fungemia was (median, ؎ s.d.) 10 ؎ 8 days. Candida glabrata (53.3%) was the most common yeast species, followed by C. krusei (33.3%), and C. parapsilosis (13.3%). Candida albicans was conspicuously absent. Ten patients (71.4%) had primary transplant-related complication (Ͼ2 days) including hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP) (n ‫؍‬ 5), severe hemorrhagic cystitis (n ‫؍‬ 3), and bacteremia (n ‫؍‬ 2). Seven (50.0%) patients expired and in three (21.4%) deaths were attributed to fungemia. The impact of a primary transplant-related complication on short-term survival in this setting was not significant (P ‫؍‬ 0.07) (HUS/TTP (P Ͼ 0.5); neutropenia (P Ͼ 0.5); GVHD (P ‫؍‬ 0.35)). Removal of CVC did not alter outcome in our group (P у0.5) although in patients with persistent fungemia (Ͼ72 h), and those with preceding bacteremia, mortality was significantly higher (P ‫؍‬ 0.002). Conventional prognosticators of poor outcome did not adversely effect short-term survival in our transplant recipients with hematogenous candidiasis. The predominance of C. glabrata and C. krusei breakthrough infections was similar to what is seen with high-dose fluconazole (400 mg) prophylaxis, and no adverse effects of low-dose fluconazole in terms of increased incidence of non-susceptible Candida species was seen. Bone Marrow Transplantation (2001) 28, 873-878.
Nosocomial fungemia due to Candida species has steadily increased over the past four decades. [1] [2] [3] [4] In recipients of blood and marrow transplantation, systemic candidiasis is a serious complication associated with high morbidity and mortality. 5, 6 Antifungal prophylaxis with fluconazole during the early post-transplantation period has been shown to significantly reduce the incidence of candidemia, 7 and improve short-term survival. 8 Fluconazole prophylaxis for extended periods (Ͼ75 days) in recipients of high-risk marrow transplantation was also beneficial. 9 Breakthrough infections in patients receiving triazolebased antifungal prophylaxis, and changes in the spectrum of Candida species have been reported sporadically during the last decade. 10, 11 Increase in the non-C. albicans fungemia in this setting was probably multifactorial although selection pressure due to fluconazole and itraconazole may have played an important role. As most nosocomial fungemia arises from the host's endogenous flora, transient or permanent changes in the colonizing yeast species in patients receiving these antimicrobial prophylaxis, was not unexpected. 12, 13 However, emergence of de novo resistance in fluconazole susceptible C. albicans following prophylaxis with triazoles was worrying. 14 At our bone marrow transplantation center, low-dose fluconazole (100-200 mg daily) is routinely included in the early post-transplant prophylaxis regimen. We report, characteristics of nosocomial fungemia in patients undergoing high-risk allogeneic marrow transplantation during 1997-1999.
Patients and methods

Study design
Retrospective review of Candida bloodstream invasion was performed in patients following allogeneic marrow transplantation at Palmetto-Richland Memorial Hospital Cancer Center, Columbia, SC, from 1 January 1997 to 31 December 1999. Patient information, and laboratory results was retrieved from patient charts and computerized hospital data systems. All blood culture specimens were processed at the Microbiology Laboratory, Palmetto-Richland Memorial Hospital, SC, USA.
Definitions
Candidemia was defined as a clinical illness associated with the presence of Candida in patients bloodstream. Presence of Candida in blood culture was considered clinically significant even in the absence of clinical signs or symptoms, especially in individuals at risk for invasive candidiasis such as agranulocytosis, uremia, hyperalimentation, prolonged exposure to multiple antibiotics, persistent hyperglycemia, uremia, severe mucositis involving oro-pharyngeal mucosa, and those receiving adrenal glucocorticoids. 15, 16 At least one positive blood culture for a single Candida species during the same hospitalization was regarded as an episode. All consecutive blood cultures with Candida during the same hospitalization obtained within 72 h were considered as a single episode. If more than one Candida species was isolated, infection due to each was considered as a separate episode.
Breakthrough fungemia was defined as the presence of Candida in a patient's bloodstream while receiving prophylactic fluconazole (100 to 200 mg daily) for greater than 48 h. 17 Persistent infection was defined as presence of Candida in blood culture specimens for greater than or equal to 72 h while receiving appropriate antifungal therapy. All patients with persistent fungemia were evaluated for secondary ocular, endovascular, and joint infections. Neutropenia was defined as absolute neutrophil count (ANC) Ͻ500 cells/mm 3 and ANC of Ͻ100 cells/mm 3 was regarded as profound granulocytopenia. Agranulocytosis was a non-detectable neutrophil count in peripheral circulation. The onset of granulocytopenia and detection of Candida species in blood culture specimens is reported as the duration of neutropenia and expressed in days. 18 Infection is interchangeably used for hematogenous candidiasis, and granulocytopenia for neutropenia throughout the text of this article. Mortality was defined as death attributable to fungemia either directly or indirectly and in the absence of other known terminal events such as intracranial hemorrhage, or septic shock resulting from infections other than invasive candidiasis. 19 Severe hemorrhagic cystitis requiring transfusion of blood and blood products, clinically stable HUS/TTP, fungal pneumonia, and rectal abscesses were not considered terminal events.
Conditioning regimen and GVHD prophylaxis
Twelve of 14 patients who lacked a matched sibling donor (MSD) underwent partially matched related donor (PMRD) marrow graft transplantation. In order to improve engraftment, total body irradiation (TBI) was increased from 1332 cGy to 1500 cGy. Etoposide (20 mg/kg) was administered once; cytosine arabinoside (3 g/m 2 ) administered twice daily ϫ six doses; cyclophosphamide (50 mg/kg) given daily ϫ two doses; high-dose methyprednisolone (1 g/m 2 ) administered every 12 h ϫ four doses. Low-dose cyclosporin (3 mg/kg) was started day Ϫ1 and levels were maintained between 100 and 200 as measured by monoclonal antibody technique and switched to the oral form after day ϩ21 and weaned gradually through the first year post-BMT; moderate-dose methylprednisolone (30 mg/m 2 ) administered before antithymocyte globulin (ATG); ATG (10 mg/kg) was given daily ϫ 12 doses on day ϩ5 to ϩ16, and steroid dose was tapered 10% weekly and switched to prednisone orally after day ϩ21. Patients were housed in a positive-pressure high efficiency particulate air (HEPA)-filtered BMT unit. All patients received granulocyte colony-stimulating factor (G-CSF) from day ϩ1 until the white blood cell (WBC) count exceeded 5000/l. Fluconazole 100 to 200 mg daily was given prophylactically either orally or intravenously in patients intolerant of oral medication. Broad-spectrum antibiotics, intravenous Ig, inhaled pentamidine or trimethoprim-sulfamethoxazole and antiviral agents were used as indicated. 20 Two patients underwent MSD marrow graft transplantation. Conditioning consisted of TBI 1200 cGy, etoposide (50 mg/kg) ϫ 1 day, and cyclophosphamide (50 mg/kg) given on day Ϫ3 and Ϫ2. Graft-versus-host disease prophylaxis was initiated on day Ϫ1, cyclosporin (3 mg/kg) to maintain serum level between 300 and 400 ng/ml; methotrexate on day ϩ1 (15 mg/m 2 ), and then reduced to 10 mg/m 2 on days ϩ3, ϩ6 and ϩ11.
Microbiology
Presumptive identification of C. albicans was performed by germ-tube test, organisms that failed to form a germ tube following 3 h of incubation at 37°C in sterile horse serum were further tested by an auxanographic plate method (BBL Microbiology Systems, Cockeysville, MD, USA). The Candida species not identified by the above methods were subjected to additional standard testing including YBC Yeast Identification Card (BioMerieux Vitek, Hazelwood, MO, USA) and APIC Biochemical Strip (BioMerieux Vitek). Mycology laboratories at the Department of Health and Environmental Control (DEHC, Columbia, SC, USA) provided extra-institutional reference for yeast not identified by the above methods.
Antifungal therapy
All clinically ill patients with candidemia received treatment with amphotericin based preparations including Abelcet (3-5 mg/kg daily) (The Lipsome Company, Princeton, NJ, USA) and Ambisome (3-5 mg/kg daily) (Fujisawa Healthcare, Deerfield, IL, USA). Upon initial identification of Candida species, intravenous fluconazole (100 to 200 mg) was given through all three lumens of the central venous catheter during the first 24 h provided the patient was not ill. During this period a decision was made regarding possible colonization of the central venous catheter or serious systemic candidiasis. In patients that fell into the latter category, treatment with an amphotericin-based agent was started promptly.
Removal of intravascular catheter
The indwelling central venous catheter was removed immediately in severely ill patients, or those receiving highdose corticosteroids for GVHD or with ATG prophylaxis. In CVCs not removed, antifungal treatment was given via all three lumens. All intravascular lines (central and peripheral) were removed in patients with candidemia for longer than 48 h.
Statistical analysis
The chi-square test and Fisher's exact test were used to determine categorical predictors of nosocomial fungemia. Differences between the categorical variables were considered significant if the two-tail P value was less than 0.05.
Results
Two hundred and four allogeneic marrow transplants were performed from 1 January 1997 to 31 December 1999. Fourteen patients developed nosocomial candidemia while receiving fluconazole (150 mg median daily dose) for greater than 7 days. The incidence of hematogenous candidiasis was 6.8 per 100 BMT; 8.4 per 100 mismatchedrelated, and 6.2 per 100 matched-related allogeneic marrow graft transplants. In 30 matched-unrelated marrow graft recipients, and 63 patients that underwent autologous peripheral stem cell reinfusion, fungemia was not observed. Eleven (78.6%) were profoundly neutropenic (ANC Ͻ100/mm 3 ) and the interval between onset of neutropenia and isolation of Candida from blood cultures was (median Ϯ s.d.) 10 Ϯ 8 days. Twelve received partial HLA-mismatched marrow grafts from related donors (PMRD). Two underwent matched-related donor (MRD) graft transplantation. The underlying cancer and patient demographic information is summarized in Table 1 . In four patients acute graft-versus host disease (GVHD) was diagnosed prior to the onset of infection. Chronic GVHD and veno-occlusive disease (VOD) was present in one each. The median duration from marrow transplantation to the diagnosis of fungemia was 12 Ϯ 288 days, including patient 13 (Table 2 ) who developed fungemia 6 weeks after receiving chemotherapy for relapsed Hodgkin's disease. An indwelling central vascular catheter (CVC) was present in all patients for longer than 7 days.
During these 36 months, 15 episodes of candidemia including two episodes in patient 10 were observed ( Table  2 ). In six patients (42.9%) fungemia persisted for greater than or equal to 72 h. Eight episodes of C. glabrata (53.3%) were most common, followed by five C. krusei (33.3%) and two C. parapsilosis (13.3%). A primary transplant-related complication was identified in 10 individuals (Table 2) . Five developed acute hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura (HUS/TTP), three had severe hemorrhagic cystitis requiring blood transfusions, and two were bacteremic. Candida esophagitis (patient 6) and relapsing rectal abscess requiring multiple surgical debridement preceded fungemia in patient 10 ( Table 2) .
Seven (50%) responded to therapy. Others expired 3 to 24 days from the last positive blood culture for a yeast. All patients in the latter group had an underlying primary transplant-related complication (P ϭ 0.07) ( Table 2 ). Both patients with bacteremia that subsequently became fungemic expired (P ϭ 0.002). Underlying agranulocytosis (P у0.5), acute GVHD (P ϭ 0.07), HUS/TTP (P у0.5), or hemorrhagic cystitis (P Ͼ0.5) did not confer poor outcome. Death was attributed directly or indirectly to hematogenous candidiasis in three patients and the duration was 3 to 7 days. Three patients (75%) expired among four that underwent removal of an indwelling central intravascular catheter. In our group intravascular catheter exchange was not associated with improved survival (P у0.5).
Discussion
Bloodstream infections in patients with profound neutropenia are associated with prolonged hospitalization, and poor short-term survival. 21, 22 Systemic fungal infections are serious complications as they carry higher morbidity and mortality compared with frequently isolated nosocomial blood borne pathogens such as Staphylococcus aureus, and Pseudomonas aeruginosa, etc. 23, 24 The initial strategies in preventing systemic yeast infections with nystatin and ketoconzole in high-risk patients were promising. 25 During the early 1990s prophylaxis with fluconazole became increasingly common due to improved bioavailability and preferred toxicity profile. 26, 27 A decline in systemic candidiasis (approximately seven cases per 100 allogeneic transplants) was observed in patients treated with fluconazole during high-risk periods. 8 This compared favorably with the incidence of candidemia in our patients (6.8/100 allogeneic BMT) in whom low-dose fluconazole (100-200 mg daily) was routinely given prophylactically during the early post-transplantation period.
This decline in the hematogenous candidiasis was Patients age is given in years. AML ϭ acute myelogenous leukemia; ALL ϭ acute lymphocytic leukemia; CML ϭ chronic lymphocytic leukemia; MM ϭ multiple myeloma; PMRD ϭ partially matched related donor graft; MRD ϭ matched related donor graft; CNS ϭ coagulase-negative staphylococcus. Cystitis ϭ severe hemorrhagic cystitis due to adenovirus or polyoma virus. a Outcome -death (in days) from the last positive blood culture for Candida; Patient 13 developed candidemia 6 weeks after receiving chemotherapy for relapsed Hodgkin's disease and 11 days later presented with bilateral C. krusei septic arthritis of knee joints.
accompanied by reports of a rise in 'difficult to treat' breakthrough systemic fungal infections. 6, [9] [10] [11] A change in the spectrum of infections due to Candida species with either low-triazole susceptibility profile or yeast with intrinsic resistance to fluconazole was concerning. [28] [29] [30] The disappearance of C. albicans and predominance of C. glabrata and C. krusei systemic infections in our hospitalized marrow transplantation recipients during recent years was not unexpected. This shift in Candida species towards virulent yeast strains with restricted triazole susceptibility profiles was linked with prior exposure to fluconazole used for prophylaxis or prolonged pre-emptive therapy. [30] [31] [32] The near exponential increase in hematogenous candidiasis due to the non-albicans Candida species may be in part due to a shift in the spectrum of yeast colonization in these high-risk individuals. Recently, we reported a marked increase in colonization due to C. glabrata in patients undergoing treatment for cancer at a comprehensive cancer center in New York. 30 In patients with hematologic malignancy and those undergoing blood and marrow transplantation, short-term survival was severely reduced in the presence of clinically significant colonization due to C. glabrata and C. krusei. 33 A shift in the spectrum of species associated with systemic candidiasis appears to directly correlate with patients endogenous yeast reservoir. 12, 13 We suspect that disappearance of bloodstream infections due to C. albicans in our highly susceptible patient population in part, reflect a change in endogenous Candida reservoirs, and also a selective protection provided by low-dose fluconazole against systemic disease due to C. albicans, C. tropicalis, and other Candida species. [30] [31] [32] [33] Breakthrough infections due to C. parapsilosis in adults are infrequent and during this study period we observed the proportion of fungemia due to C. parapsilosis was less than 15% (Table 2 ). This was in contrast to a sharp rise in C. parapsilosis bloodstream infections reported in patients at cancer centers from the USA, Latin America, and Europe. [34] [35] [36] [37] The reason for this increase in C. parapsilosis infections among non-surgical, non-pediatric, high-risk patients with an underlying malignancy remains uncertain. 34 During the past 3 years, half of our fungemic transplant recipients expired. In three, death was attributed due to fungemia ( Table 2 ). The overall response to antifungal therapy in our group was good. This was in contrast to higher mortality reported in patients with C. glabrata and C. krusei systemic infections at another center. 2, 6, 10, 11, 38 During this retrospective study, 71% had a preceding primary marrow transplant-related complication (Table 2) . Survival in patients with an ongoing complication such as acute GVHD (P ϭ 0.07), severe hemorrhagic cystitis requiring blood transfusions (P Ͼ0.5), HUS/TTP (P Ͼ0.5), and profound granulocytopenia (P у0.5) was not significantly altered. Surprisingly, removal of indwelling intravascular catheters did not significantly change outcome in our patients either (P у0.5). However, in patients with Candida isolation for longer than 72 h following initial diagnosis (persistent infection), short-term survival was markedly compromised (P ϭ 0.002). Similarly, patients with preceding bacteremia had a higher mortality in this setting (P ϭ 0.002).
In conclusion, an overall benefit of low-dose fluconazole prophylaxis appears to be comparable to experience reported with higher doses at other centers. 8, 9 We did not observe an unfavorable outcome in patients with systemic candidiasis due to highly virulent yeasts or Candida species with restricted antifungal susceptibility profiles. In patients with primary transplant-related complication such as acute GVHD, HUS/TTP, neutropenia, and severe hemorrhagic cystitis, short-term survival was not significantly altered. However, survival was markedly compromised in the setting of concurrent bacteremia and those with persistent hematogenous candidiasis following high-risk allogeneic marrow transplantation.
